Fortuna Mining Corp. Common Shares vs Mesoblast Limited — how do they compare? Fortuna Mining Corp. Common Shares trades at $10.96 (market cap $3.13B), while Mesoblast Limited trades at $14.3 (market cap $1.75B). The key difference: Fortuna Mining Corp. Common Shares is the larger of the two by market cap, and Fortuna Mining Corp. Common Shares is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortuna Mining Corp. Common Shares for 1 Days and Mesoblast Limited for 15 Days on average.
| FSM | MESO | |
|---|---|---|
Market Cap | $3.13B | $1.75B |
Volume | 6,504,680 | 239,027 |
Sector | Basic Materials | Health |
52-Week High | $13.66 | $20.96 |
52-Week Low | $7.84 | $13.19 |
Typical Hold Time | 1 Days | 15 Days |
Enterprise Value | $2.75B | $1.83B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Trailing returns across standard periods
Fortuna Mining is a Canadian precious-metals mining company with operations in Latin America and West Africa. It produces gold and silver and conducts exploration activities in several countries.
Read more on FSM →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →